Information Provided By: 
Fly News Breaks for June 16, 2016
AVEO
Jun 16, 2016 | 06:06 EDT
Piper Jaffray analyst Edward Tenthoff says Pharmstandard's decision to terminate its development and commercialization agreement for tivozanib in Russia does not impact the valuation of AVEO Oncology. Importantly, milestones under the deal were not included in AVEO's cash guidance, Tenthoff tells investors in a research note. The analyst notes he did not include any value for sales in the terminated territories into his model. Tenthoff reiterates an Overweight rating on AVEO with a $1.70 price target.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
